Citations

Clear

115 citation(s) found for "Rosenfeld, A B".

Intracranial Targeting of Cholesterol Processing Reveals a Therapeutic Vulnerability that Reprograms Glioblastoma and Promotes Antitumor Immunity
Ulloa-Navas, María José , Whitehead, Rachel Melanie, Jones, Vanessa K. , Michaelides, Loizos , Brooks, Mieu, Basil, Aleeshba , Morales‐Gallel, Raquel , Gomez-Palmero, Cristina , Reynaga-Macias, Graciela Abril , Sánchez-Garavito, Jesús E. , Tapia-Dierking, Brianna, Nair, Asha, Llano, Juan Pablo Navarro Garcia de, Dryden, Ian, Rosenfeld, Steven S. , Ren, Yingxue , Quiñones‐Hinojosa, Alfredo , Sánchez-Garavito, Jesús E , Whitehead, Rachel, Llano, Juan Pablo Navarro Garcia de, Schiapparelli, Paula , Dryden, Ian, Clark, Victoria Elizabeth , Dong, Haidong , Deleyrolle, Loic P. , Qin, Hong , Herranz‐Pérez, Vicente , García‐Verdugo, José Manuel

Mayo Clinic

No container title available | August 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.18.745568 Get It

Abstract Glioblastoma (GBM) remains the most lethal primary brain cancer due to its remarkable metabolic plasticity and therapeutic resistance. Here, we identify cholesterol dependency as a therapeutically exploitable vulnerability in GBM using two FDA-approved drugs: the H1 histamine antagonist clemastine and the retinoid X receptor agonist bexarotene. Combined treatment induces potent synergistic anti-tumor activity across patient-derived glioma models, suppressing proliferation, stemness, and survival at sub-IC50 concentrations. Mechanistically, this therapy disrupts cholesterol biosynthesis, transport, and homeostasis, triggering endoplasmic reticulum stress and activation of the unfolded protein response, ultimately leading to autophagy and apoptotic cell death. Orthotopic patient-derived glioma models recapitulate these mechanisms in vivo, where local intracranial administration significantly reduces tumor progression and prolongs survival using fourfold lower doses than systemic intraperitoneal delivery. Single-cell RNA sequencing revealed activation of regeneration and plasticity programs, accompanied by immune microenvironment remodeling and enhanced inflammatory signaling. Importantly, syngeneic models preserved immune cell composition, supporting future integration with immunotherapeutic strategies. Together, these findings establish cholesterol dysregulation–induced metabolic collapse as a promising therapeutic approach for GBM.
A phosphorylation switch governs KIF11’s mechanical output during mitosis
Šemić, Amila , Reddy, Babu J.N., Muretta, Joseph M. , Vandal, Sarah E. , Thompson, Alex F. , Fonseca, Cindy L., Rosenfeld, Steven S. , Gross, Steven P. , Stumpff, Jason

Mayo Clinic

Proceedings of the National Academy of Sciences | August 11, 2026 | Volume: 123 | Issue: 33 | Pages: No page available

10.1073/pnas.2602415123 | PMID 42579498 Get It

The kinesin-5 motor protein KIF11 is crucial for mitotic spindle assembly, driving the separation of spindle poles through microtubule sliding. Src-family kinases phosphorylate KIF11 at multiple tyrosine residues within its motor domain, but the mechanistic consequences of these modifications remain unclear. Here, we dissect the role of phosphorylation at Y211 using phospho-mimetic (Y211E) and nonphosphorylatable mutants (Y211F) in biochemical, biophysical, and cellular assays. Optical trapping and Förster resonance energy transfer analyses reveal that Y211 phosphorylation slows neck-linker docking, reducing motor velocity and force generation under load. In human cells, Y211E expression impairs bipolar spindle formation and decreases spindle pole separation velocity, while Y211F shortens steady-state spindle length. Fluorescence recovery after photobleaching analyses show that Y211E accelerates motor turnover on spindle microtubules, consistent with the mutant motor’s heightened load sensitivity. Together, these findings support a model in which Src-mediated phosphorylation at Y211 acts as a rheostat to tune KIF11 mechanochemistry and spindle assembly dynamics, linking cancer-relevant kinase signaling to mitotic force generation.
Glioblastoma Subtypes Exhibit Distinct Migration Mechanics and Immune Responses
Shamsan, Ghaidan A. , Liu, Chao J. , Braman, Brooke C. , Li, Ruyi , Rathe, Susan K. , Sarver, Aaron L. , Ghaderi, Nima , McMahon, Mariah , Klank, Rebecca L. , McFarren, S Joseph. , Masopust, David , Clark, H. Brent , Rosenfeld, Steven S. , Largaespada, David A. , Tschida, Barbara R , McFarren, S Joseph , Rosato, Pamela C , Masopust, David , Sarkaria, Jann N , Clark, H Brent , Rosenfeld, Steven S , Largaespada, David A. , Odde, David J , Shamsan, Ghaidan A , Liu, Chao J. , Rathe, Susan K. , Sarkaria, Jann N.

Mayo Clinic

Cancer Research Communications | July 14, 2026 | Volume: 6 | Issue: 8 | Pages: 1898-1915

10.1158/2767-9764.crc-25-0579 | PMID 42447444 Get It

Abstract Glioblastoma (GBM) remains a deadly cancer driven in part by invasion of tumor cells into the brain. Transcriptomic analyses have identified distinct molecular subtypes, but mechanistic differences that account for clinical differences are not clear. In this study, we show that, as predicted by the motor-clutch model of cell migration, mesenchymal glioma cells are more spread, generate larger traction forces, and migrate faster in brain tissue compared with proneural cells. Despite their rapid migration and comparable proliferation rates in vitro, mice with mesenchymal tumors survive longer than those with proneural tumors. This improved survival correlated with an immune response in mesenchymal tumors, including T cell–mediated. Consistently, inducing mesenchymal tumors in immunodeficient mice resulted in shorter survival, supporting a protective immune role in mesenchymal tumors. Thus, mesenchymal tumors have aggressive migration but are immunologically “hot,” which suppresses net proliferation. These two features counteract each other and may explain the lack of a strong survival difference between subtypes clinically, while also opening up new opportunities for subtype-specific therapies. Significance: This study highlights new mechanical and immunologic insights into GBM molecular subtypes using an integrated modeling–genome engineering strategy, which can potentially facilitate GBM subtype-specific therapeutic strategies.
Microtubule Acetylation Regulates the Malignant Phenotype of Glioblastoma and is a Promising Therapeutic Target
Dovas, Athanassios, Bhattacharya, Santanu, Kulkarni, Tanmay, Amini, Misha, Haddock, Ashley, Nagaiah, Naveen KH, Mukhopadhyay, Debrabrata, Suarez-Meade, Paola, Quinones-Hinojosa, Alfredo, Canoll, Peter, Kenchappa, Rajappa, Rosenfeld, Steven S. , Rosenfeld, Steven S , Zarco, Natanael , Bhattacharya, Santanu , Kulkarni, Tanmay, Liu, Yi , Haddock, Ashley , Nagaiah, Naveen K H, Suárez-Meade, Paola , Quiñones‐Hinojosa, Alfredo , Miller, Courtney A. , Kamenecka, Theodore M. , Canoll, Peter, Kenchappa, Rajappa S.

Mayo Clinic

No container title available | June 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.15.732342 Get It

ABSTRACT Glioblastoma (GBM) is universally lethal despite decades of research to find effective treatments. This highlights the need to identify druggable targets essential for sustaining the malignant phenotype but dispensable for normal tissue. We propose that the enzyme α-tubulin acetyl transferase ( ATAT1 ) meets these criteria. ATAT1 acetylates α-tubulin at lysine 40, which increases microtubule stability and promotes microtubule-based transport. While ATAT1 knockout mice have only a very mild phenotype, ATAT1 suppression in GBM has multiple therapeutic effects by reducing tumor invasion, proliferation, and therapeutic resistance. These translate not only into improved survival with ATAT1 targeting by itself, but also into synergy when ATAT1 deletion is combined with FDA approved therapies. This study strongly supports our conclusion that ATAT1 is a promising therapeutic target in GBM.
The clinical utility of functional testing in fibroblasts to diagnose primary mitochondrial disease
Hove, Johan L.K. Van , Friederich, Marisa W. , Hove, Roxanne A. Van , Lee, Jessica C. , Knight, Kaz M. , Donovan, Tonia E, Silveira, Lori, Hirano, Michio, Abdenur, José E. , Cassiman, David, Cohen, Bruce H. , Elsea, Sarah H. , Enns, Gregory M., Gahl, William A, Gavrilova, Ralitza, Geddes, Gabriella C, Glamuzima, Emma E, Goldstein, Amy , Haas, Richard , Khan, Aneal , Kripps, Kimberly A. , Lehman, April, Lichter-Konecki, Uta, Morava, Eva, Rosenfeld, Jill A, Saneto, Russel P., Scaglia, Fernando , Shelkowitz, Emily , Smith, Wendy E, Soler-Alfonso, Claudia, Coster, Rudy N.A. Van, Vockley, Gerard, Wigby, Kristen, Wolfe, Lynne A. , Wortmann, Saskia B. , Van Hove, Johan L K , Ganetzky, Rebecca D , Cohen, Bruce H , Elsea, Sarah , Khan, Aneal , Larson, Austin A , Lehman, April N , Mayr, Johannes A , Scaglia, Fernando , Simon, Mariella , Smet, Joél E G , Tarnopolsky, Mark , Wolfe, Lynne A , Wortmann, Saskia , Yang, Jennifer H , Donovan, Tonia E., Ganetzky, Rebecca , Hirano, Michio , Butler, Merlin G. , Cassiman, David , Enns, Gregory M. , Gahl, William A. , Glamuzina, Emma E , Larson, Austin , Lichter‐Konecki, Uta , Morava, Éva , Peterson, James T. , Rosenfeld, Jill A. , Saneto, Russell P. , Smith, Wendy E. , Soler‐Alfonso, Claudia , Tarnopolsky, Mark A. , Vanlander, Arnaud Vincent , Vermeersch, Pieter , Wigby, Kristen M. , Yang, Jennifer H.

Mayo Clinic

No container title available | June 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.12.26355546 | PMID 42369463 Get It

Abstract Genome sequencing of the heterogeneous primary mitochondrial disorders (PMD) frequently reveals variants of uncertain significance that require functional tests for diagnosis, and does not identify variants in all patients. We analyzed mitochondrial enzyme assays, blue native polyacrylamide gel electrophoresis (BN-PAGE) with in-gel activity staining, complex I assembly blot, and select protein abundances in fibroblasts of a case series of 204 PMD patients divided into functional classes, in comparison to 51 controls and 53 differential diagnostic conditions. Overall, sensitivity and specificity for respiratory chain enzyme assays were 46% and 93% respectively, for BN-PAGE 40% and 98%, for complex I assembly assay 49% and 99%. The overall sensitivity of all tests was 76%, specificity 93%, with positive predictive value 96% and negative predictive value 67%. Categories with high sensitivity were isolated complex deficiencies, nuclear DNA-encoded mitochondrial protein synthesis defects, co-factor defects, and mitochondrial amino-acyl-tRNA synthetase conditions when aided by protein abundance. Mitochondrial DNA mutations and maintenance disorders showed poor sensitivities. Secondary dysfunctions were rare. A complete battery of functional tests showed strong diagnostic clinical utility in fibroblasts. One sentence summary A combination of four mitochondrial functional tests to identify or confirm suspected primary mitochondrial disease in fibroblasts had good sensitivity and excellent specificity, well beyond what was perceived using enzyme assays only.
Multi-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma
Garcia, David M., Lin, Wan‐Hsin , Wickland, Daniel P. , Jessen, Erik , Middlebrooks, Erik H. , Haydu, Lauren E. , Brooks, Mieu , Feathers, Ryan W. , Kinsella, Lindsey , Sereduk, Chris , Rosenfeld, Steven S. , Chaichana, Kaisorn L. , Anastasiadis, Panos Z. , Quiñones‐Hinojosa, Alfredo , Jessen, Erik , Tran, Nhan L , Chaichana, Kaisorn L , Anastasiadis, P Z , Quinones-Hinojosa, Alfredo , Middlebrooks, Erik H , Tran, Nhan L.

Mayo Clinic

Neuro-Oncology | June 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/neuonc/noag139 | PMID 42296327 Get It

Abstract Background Glioblastoma (GBM) remains a devastating cancer with limited treatment options, largely due to its heterogeneity. While supramaximal resection has recently provided survival benefits, therapeutic profiling of different tumor compartments, particularly its infiltrative edge remains largely unexplored. Methods Here, we leveraged magnetic resonance imaging (MRI)-guided multi-sampling, collecting 2 cores and 2 margins per case, to query GBM heterogeneity. Whole-exome and RNA-seq with drug testing in two patient-derived 3D models were used to reveal similarities and differences in genomic and transcriptomic makeups, cellular compositions, and drug responses across cores and margins. Bioinformatics interrogations further identified response biomarkers. Results Mutation analysis showed that oncogenes exhibited a higher degree of spatial heterogeneity than tumor suppressor genes, regardless of MRI status. While the mesenchymal transcriptional subtype with extracellular matrix remodeling, stress response, and immune programs were preferentially enriched in enhancing cores, proneural tumors with neurological processes favored non-enhancing margins. Using a 15-drug GBM-targeted panel, ERK (ulixertinib) and PI3K pathway (paxalisib, CC-115) inhibitors showed preferential efficacy in enhancing cores and non-enhancing margins, respectively. The anti-apoptosis, pan-Bcl2 agent navitoclax and the epigenetic drug trotabresib represented the most effective, tumor-wide monotherapies. Importantly, drug combinations generally outperformed single agents across all regions. Conclusions This work demonstrates the regional heterogeneity of therapeutic vulnerabilities in GBM ex vivo, showing various drugs with tumor-wide or MRI-enhancement informed activity. These findings offer preclinical bases of numerous monotherapies and drug combinations for future clinical trial design.
NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026
Spratt, Daniel E., Srinivas, Sandy, Ahmed, Bilawal, An, Yi , Bitting, Rhonda, Chapin, Brian, Cheng, Heather H., D’Amico, Anthony Victor, Desai, Neil, Dorff, T. B., Eastham, James A., Farrington, Thomas A., Gao, Xin, Gupta, S, Karnes, R. Jeffrey, Kishan, Amar U., Kuettel, Michael, Lang, J., Lee, Daniel, Lotan, Tamara, McDonald, Andrew, Morgan, Todd M. , Pessoa, Rodrigo, ROACH, M, Robin, Tyler, Rosenfeld, Stan, Scarpato, Kristen R., Seibert, Tyler, Shabsigh, Ahmad, Szmulewitz, Russell, Tward, Jonathan, Valicenti, Richard, VanderWeele, David, Wong, J.K. , Kovách, E, Freedman-Cass, Deborah, Morgan, Todd M , Robin, Tyler P. , Spratt, Daniel E. , Adra, Nabil , Bitting, Rhonda L. , Chapin, Brian F. , Cheng, Heather H., Cho, Steve Y. , D’Amico, Anthony V. , Dorff, Tanya B. , Eastham, Jeff , Gupta, Shilpa , Ippolito, Joseph E. , Kishan, Amar U. , McDonald, Andrew M. , Rais‐Bahrami, Soroush , Roach, Mack , Scarpato, Kristen R., Shabsigh, Ahmad , Szmulewitz, Russell Z , Teply, Benjamin A. , Tward, Jonathan D. , Valicenti, Richard K., VanderWeele, David James , Freedman-Cass, Deborah A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 14, 2026 | Volume: 24 | Issue: 5 | Pages: 140-149

10.6004/jnccn.2026.0023 | PMID 42134408 Get It

The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel’s discussions on select 2026 updates to the guidelines regarding nonmetastatic disease: the elimination of the very-low-risk group, updates to the Principles of Active Surveillance, and caution in the use of focal therapy in newly diagnosed patients.
Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomas
Lin, Wan-Hsin, Kosari, Farhad , Smadbeck, James B. , Barrett, Michael T. , Feathers, Ryan, Hall, Jamie, Sadeghian, Dorsay , Johnson, Sarah H. , Harris, Faye R. , Berry, Taylor, McCune, Alexa, Murphy, Stephen James, Kinsella, Lindsey, Ensign, Shannon P. Fortin, Yang, Lin , Emanuel, Angela, Jones, Leila A., Schaefer-Klein, Janet, Ida, Cristiane M., Sherman, Wendy, Porter, Alyx B. , Rosenfeld, Steven, Kizilbash, Sani H., Jaeckle, Kurt A. , Mrugala, Maciej M., Borad, Mitesh, Bendok, Bernard R., Quiñones-Hinojosa, A., Cheville, John C. , Vasmatzis, George , Anastasiadis, Panos Z. , Ensign, Shannon P. Fortin , Mansfield, Aaron S , Ensign, Shannon P. Fortin , Sotiriou, Sotiris , Haydu, Lauren E. , Moniz‐Garcia, Diogo , Ida, Cristiane M., Salomao, Marcela , Kizilbash, Sani H. , Mrugala, Maciej M., Mansfield, Aaron S. , Borad, Mitesh J. , Bendok, Bernard R. , Burns, Terry C. , Quiñones‐Hinojosa, Alfredo

Mayo Clinic

No container title available | February 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.01.701806 | PMID 41676502 Get It

Abstract High-grade gliomas (HGGs) are aggressive tumors with poor outcomes and limited treatment options. Here, we combined genomic and transcriptomic tumor profiling with drug testing in a patient-derived 3-dimensional culture model to identify individualized treatments and predictive biomarkers. Activity of single agents targeting frequently dysregulated glioma pathways was relatively poor ex vivo and generally reflected historical patient data. However, compounds targeting PI3K, epigenetic, and survival/senescence signaling were effective in some cases. Drug sensitivity correlated with transcriptional rather than genomic features and suggested heterogeneity as a resistance mechanism. Bromodomain and extraterminal domain inhibition was particularly effective in tumors enriched in the mesenchymal transcriptional subtype, promoted proneural transition, and was overcome by upregulated PI3K signaling. Notably, combinations were largely effective, with 6 strategies exhibiting stronger efficacy than corresponding single agents in most cases (58-77%). This study identifies HGG vulnerabilities and associated biomarkers, resistance mechanisms, and effective combination strategies that warrant further clinical validation. Graphical Abstract
A Phosphorylation Switch Governs KIF11’s Mechanical Output During Mitosis
Šemić, Amila , Reddy, Babu Jn, Muretta, Joseph M. , Vandal, Sarah E. , Thompson, Alex F. , Fonseca, Cindy L., Rosenfeld, Steven S. , Gross, Steven P. , Stumpff, Jason , Reddy, Babu J.N.

Mayo Clinic

No container title available | January 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.23.700875 | PMID 41648279 Get It

Abstract The kinesin-5 motor protein KIF11 is crucial for mitotic spindle assembly, driving the separation of spindle poles through microtubule sliding. Src-family kinases phosphorylate KIF11 at multiple tyrosine residues within its motor domain, but the mechanistic consequences of these modifications remain unclear. Here, we dissect the role of phosphorylation at Y211 using phospho-mimetic (Y211E) and non-phosphorylatable mutants (Y211F) in biochemical, biophysical, and cellular assays. Optical trapping and Förster resonance energy transfer (FRET) analyses reveal that Y211 phosphorylation slows neck-linker docking, reducing motor velocity and force generation under load. In human cells, Y211E expression impairs bipolar spindle formation and decreases spindle pole separation velocity, while Y211F shortens steady-state spindle length. Fluorescence recovery after photobleaching (FRAP) analyses show that Y211E accelerates motor turnover on spindle microtubules, consistent with the mutant motor’s heightened load sensitivity. Together, these findings support a model in which Src-mediated phosphorylation at Y211 acts as a rheostat to tune KIF11 mechanochemistry and spindle assembly dynamics, linking cancer-relevant kinase signaling to mitotic force generation.
Clinical utility of ECAP dosing in a real-world population delivered via EVOKE therapy: the ECAP study
Pope, Jill , Smith, Gregory L. , Goree, Johnathan , Mekhail, Nagy , Levy, Robert M. , Deer, Timothy R. , Vu, Chau , Shah, Jarna R , Costandi, Shrif , Rosen, Steven M., Bromberg, Todd A., Patel, Atish, Latif, Usman , Lad, Shivanand P. , Jameson, Jessica , Calodney, Aaron , Falowski, Steven , Smith, J. Carson , Guirguis, Maged , Boeding, Ronald B., Sprintz, Michael, Antony, Ajay, Patterson, Denis G., Laufer, Andras, Pilitsis, Julie G. , Miller, Nathan , Rosenfeld, David J. , Tate, Jordan L, Raslan, Ahmed M. , Kallewaard, Jan Willem , Leitner, Angela , Hanson, Erin, Soliday, Nicole, Petersen, Erika , Goree, Johnathan A , Mekhail, Nagy A , Costandi, Shrif J , Lam, Christopher M , Hayek, Salim , Hagedorn, Jonathan M , Kallewaard, Jan Willem , Duarte, Rui , Deer, Tim , Shah, Jarna , Rosen, Steven M, Sayed, Dawood , Lam, Christopher , Hayek, Salim M. , Hagedorn, Jonathan M. , Heros, Robert , Miller, Nathan, Tate, Jordan L, Hanson, Erin, Duarte, Rui

Mayo Clinic

Regional Anesthesia & Pain Medicine | December 2, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107051

10.1136/rapm-2025-107051 | PMID 41330601 Get It

Background The efficacy of EVOKE therapy, a closed-loop spinal cord stimulation (SCS) system, has been demonstrated in a double-blinded randomized controlled trial (RCT). RCT evidence, however, may not be generalizable to clinical practice, while limitations of real-world evidence may affect its validity. The aim of this study was to evaluate the effectiveness of EVOKE therapy in routine clinical practice employing a rigorous data collection approach. Methods The ECAP study was a prospective, multicenter, single-arm, pragmatic study that enrolled SCS candidates with chronic, intractable trunk and/or limb pain in 22 US investigational sites. PROMIS-29 questionnaire and objective neurophysiological metrics were collected, and minimal clinically important differences (MCIDs) were used to characterize baseline dysfunction and response to EVOKE therapy both at trial end and maximal analgesic effect post-implant visit. Pre-specified subgroup analyses were conducted based on diagnosis. Results EVOKE therapy observed included a dose ratio of 1.3 and neural dose accuracy of 2.8 μV. Improvements of >1 MCID were observed for all domains and improvements of ≥2 MCIDs were observed for six of the seven domains. Improvements observed at trial end were maintained or improved at post-implant visit, with statistically significant improvement in holistic MCID (MD 0.2, 95% CI 0.1 to 0.4, p=0.004), and a significantly greater proportion of patients considered holistic MCID responders (p=0.047). Subgroup analysis by diagnosis showed similar outcomes. Conclusions EVOKE therapy was associated with clinically meaningful improvements in a real-world chronic pain population across different subgroups and disease pathologies, with effects observed at trial end reproduced at post-implant visit.